Genscript Biotech Corporation GNNSF
Set alert
4.50 USD 0.00 0.00%
As of Nov 2, 10:19 AM ET
4.50 Day range 4.50
1.30 52-week range 6.55
- YTD
- +171.08%
- 1 year
- +147.25%
- Open
- 4.50
- Prev close
- 4.50
- Mkt cap
- 10.26B
- Vol
- 250
- Avg vol
- 1.36K
- EPS
- -0.29
- P/E
- 0.00
More statistics
- Low
- 4.50
- High
- 4.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 15, 2026 | Dec 31, 2025 | -0.03 | -0.23 | -0.20 | -666.67% |
| Aug 17, 2025 | Jun 30, 2025 | 0.08 | -0.0216 | -0.10 | -127.00% |
| Mar 11, 2025 | Dec 31, 2024 | -0.01 | 1.48 | +1.49 | +14,900.00% |
| Aug 9, 2024 | Jun 30, 2024 | -0.01 | -0.0827 | -0.07 | -727.00% |
| Mar 10, 2024 | Dec 31, 2023 | -0.05 | -0.032 | +0.02 | +36.00% |
News
- Genscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call Transcript
- Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
- GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
- Genscript Biotech Corporation (GNNSF) Q2 2025 Earnings Call Transcript
- GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
- GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
- GenScript Biotech Corporation Reports FY 2024 Results
- The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
- GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
- GenScript Biotech Corporation (GNNSF) Q2 2024 Earnings Call Transcript
Your note
Sign in to keep a note on GNNSF — it syncs with the Stock Master app.